Developer docs
API playgroundTry for free, no card

Search company profiles

Epic Therapeutics

Full company profile

uuid00032ro

Namestring
Epic Therapeutics
Legal namestring
Epics Therapeutics SA
Company typeenum
Private
Founded yearint
2018
Descriptiontext

EPICS Therapeutics SA is a Belgian clinical-stage biotechnology company founded in April 2018 and headquartered in Gosselies, Belgium. The company develops a pipeline of small-molecule therapeutics targeting RNA epigenetic regulation — specifically the m6A epitranscriptome via METTL3 inhibition — and complementary G-protein-coupled receptor (GPCR) pathways for the treatment of cancer and autoimmune/inflammatory disease. Its lead clinical candidate, EP102, is an oral, selective, best-in-class METTL3 inhibitor that entered first-in-patient trials in September 2025 across 12 hospital sites in 5 European countries (Belgium, Netherlands, Spain, Czech Republic, France), targeting advanced solid tumors including NSCLC, pancreatic, ovarian, and colorectal cancer. The pipeline also includes EP282, a first-in-class oral FFAR2 agonist for autoimmune disease (Phase I completed, positioned as Phase II-ready), and EP601, an oral GPR84 agonist in preclinical development for immuno-oncology and neuroinflammation. EPICS also operates the wholly-owned EuroscreenFast Business Services Unit, which offers GPCR screening services to external pharma and biotech clients.

The company's underlying technology platforms combine an "epitranscriptome" target class (RNA-modifying enzymes that write, read, or erase m6A marks) with GPCR modulation, intentionally positioning the company beyond DNA- and protein-targeted approaches. Pipeline assets were largely seeded by the December 2018 acquisition of Ogeda SA's assets, and the operational team — including the inventor of fezolinetant — carries significant prior drug-development experience.

The business model is pre-revenue and discovery-and-development oriented, with future revenue expected to come from product sales following regulatory approval and potential licensing or partnership transactions. There is no direct pricing or commercial sales operation; distribution today occurs via regulated clinical trial channels in Europe, with an additional service-revenue stream from EuroscreenFast's GPCR screening unit. Go-to-market is enterprise-style, with direct engagement of oncology Key Opinion Leaders, academic medical centers, and regulators, supplemented by scientific conferences (AACR, ASH, EORTC), peer-reviewed publications, and BIO investment conventions for investor and partner visibility.

Short descriptiontext

Epic Therapeutics (EPICS) is a Belgian clinical-stage biotechnology company developing small-molecule METTL3 inhibitors (lead EP102) and GPCR modulators (EP282, EP601) to treat advanced solid tumors and autoimmune/inflammatory diseases. Founded 2018, headquartered in Gosselies, Belgium; lead asset entered first-in-patient trials in 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGosselies, Belgium
HQ citystring
Gosselies
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, RNA epigenetics drugs, METTL3 inhibitor oncology, clinical stage biotechnology, epitranscriptome drug discovery
Industry3 codes
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development
TypeOne Time License
Description

EPICS Therapeutics is a pre-revenue clinical-stage biotechnology company developing small molecule therapeutics. Revenue will be generated through product sales following regulatory approval, as well as potential licensing deals and partnerships for its pipeline programs.

epicstherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Epic Therapeutics is a clinical-stage biotechnology company developing small-molecule drugs targeting RNA epigenetics (epitranscriptome) and GPCR pathways for cancer and autoimmune disease. Its lead asset EP102 is a best-in-class, orally available METTL3 inhibitor now in first-in-patient clinical evaluation in solid tumors (NSCLC, pancreatic, ovarian, colorectal), supported by Phase II-ready EP282 (FFAR2 agonist) and preclinical EP601 (GPR84 agonist).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • EP102 demonstrated near-complete tumor growth suppression in xenograft studies
+3 more records
Product overview1 text field

EPICS Therapeutics is a clinical-stage biotechnology company developing a pipeline of small-molecule drugs targeting RNA epigenetics and G-protein-coupled receptor (GPCR) mechanisms for cancer and autoimmune disease treatment. The core portfolio includes EP102 (METTL3 inhibitor, first-in-patient clinical trial for solid tumors), EP282 (FFAR2 agonist, Phase II ready for autoimmune diseases), and EP601 (GPR84 agonist, preclinical for oncology and autoimmune diseases). The RNA epigenetics platform targets the epitranscriptome to modulate RNA processing and gene expression, while the GPCR program extends this epigenetic vision to complementary signaling pathways.

Product and service4 records
1EP102 (METTL3 Inhibitor)
CategoryOncology small-molecule drug candidate
Description

Best-in-class, potent, selective, and orally available small-molecule inhibitor of the METTL3 enzyme that installs the m6A mark on messenger RNA, reprogramming tumor biology at the RNA level. EP102 is the company's lead clinical candidate for advanced solid tumors including NSCLC, pancreatic, ovarian, and colorectal cancers.

2EP282 (FFAR2 Agonist)
CategoryAutoimmune / inflammatory small-molecule drug candidate
Description

First-in-class small-molecule FFAR2 (Free Fatty Acid Receptor 2) agonist targeting the microbiome-immune axis for treatment of autoimmune and inflammatory diseases, including ulcerative colitis and C. difficile infection; also has potential in colorectal cancer. Ready for Phase II clinical development.

3EP601 (GPR84 Agonist)
CategoryImmuno-oncology / autoimmune small-molecule drug candidate
Description

Potent, selective, and orally available GPR84 agonist designed to activate or restrain immune responses, positioned at the intersection of metabolism, inflammation, and innate immunity, with therapeutic potential in oncology (tumor microenvironment reprogramming) and autoimmune diseases. In active preclinical development.

4EuroscreenFast GPCR Screening Services
CategoryDrug discovery services (GPCR screening)
Description

GPCR screening and assay development services offered to worldwide pharma and biotech clients through Epic's wholly-owned EuroscreenFast Business Services Unit.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-08
Description

Computational drug design partnership where Cresset's integrated modeling workflow combining molecular modeling and proprietary technology (Electrostatic Complementarity) accelerated the discovery and optimization of EPICS' METTL3 inhibitor compounds. The iterative process of in silico design and biological testing supported efficient hit identification and lead optimization.

2Ogeda SA (Astellas acquisition)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

EPICS acquired Ogeda SA's former assets in December 2018, including research stage programs and the EuroscreenFast Business Services Unit. Ogeda's former CEO Jean Combalbert became CEO of EPICS. Several key EPICS team members (including Graeme Fraser, Guillaume Dutheuil, Vincent Lannoy, Catherine Sorlet) previously worked at Ogeda, which was acquired by Astellas for 800M EUR in 2017.

epicstherapeutics.com
3François Fuks (ULB Cancer Research Center)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical Scientific Advisor to EPICS - Professor at Free University of Brussels and Director of ULB Cancer Research Center. His work is devoted to epigenetics and its role in cancer. Performed doctoral research at German Cancer Research Center under Harald zur Hausen (2008 Nobel Prize in Medicine). Serves as scientific founder/advisor providing expertise in epigenetics.

epicstherapeutics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical Advisory Board members from MSK: David A. Scheinberg (Vincent Astor Chair, Deputy Director for Therapeutic Discovery at Sloan Kettering Institute) and Omar Abdel-Wahab (Evin Family Chair of Molecular Pharmacology, Chair of Molecular Pharmacology Program). Both are physician-scientists specializing in novel therapeutic approaches for leukemia and cancer with extensive research programs.

5VHIO (Vall d'Hebron Institute of Oncology) - Elena Garralda
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical Advisory Board member Elena Garralda serves as Director of Molecular Cancer Therapy Research Unit (UITM) - CaixaResearch, Co-Director of Clinical Research Program, and Head of Early Drug Development at VHIO. She coordinates phase I program with expertise in immuno-oncology and first-in-human studies.

epicstherapeutics.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical Advisory Board member Rab Prinjha is currently Chief Research and Development Officer at Curve Therapeutics, former head of GSK's Immunology Research Unit and elected fellow of the Academy of Medical Sciences. Has extensive record of successful leadership with multiple first-in-class epigenetic target inhibitors progressed from discovery to beyond Phase 2.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

STORM Therapeutics is the closest direct competitor to EPICS in RNA epitranscriptomics, developing small-molecule METTL3 inhibitors (STC-15) that are also in Phase I clinical trials for solid tumors and leukemia. Both companies target the same epitranscriptome mechanism with oral small molecules.

TypeDirect peer
Description

Accent Therapeutics develops precision oncology drugs targeting RNA-modifying proteins including METTL3 and other epitranscriptome regulators. As a US-based, well-capitalized competitor in the same therapeutic axis, it is directly comparable to EPICS' EP102 program.

TypeEmerging player
Description

Tango Therapeutics is a clinical-stage oncology biotech focused on synthetic lethal targets, with a similar small-molecule targeted oncology strategy and similar stage profile as EPICS. While mechanism differs, the business model and target patient populations overlap substantially.

TypeEmerging player
Description

Repare Therapeutics develops precision oncology drugs targeting DNA damage response pathways — directly overlapping with EPICS' positioning of EP102 in tumors where METTL3 dysregulation intersects with DDR pathways. Both companies are clinical-stage with similar oncology indications in scope.

5Domain Therapeutics
TypeDirect peer
Description

Domain Therapeutics is a French biotech specializing in GPCR drug discovery and development, directly comparable to EPICS' GPCR programs (EP282 FFAR2, EP601 GPR84) and its inherited EuroscreenFast GPCR screening capabilities. Both operate in European biotech ecosystems with similar GPCR target portfolios.

TypeDirect peer
Description

Twentyeight-Seven Therapeutics focused on RNA modifying proteins (initially METTL3) for oncology before being acquired by Roche. Directly comparable to EPICS as a small-molecule developer targeting RNA epigenetic regulators in cancer.

7Sosei Heptares
TypeBroad incumbent
Description

Sosei Heptares is a leading GPCR-targeted therapeutics company with a broader portfolio than EPICS' GPCR programs (EP282, EP601). It provides a benchmark for the commercial potential of GPCR-focused drug discovery and is comparable on the GPCR technology axis.

TypeBroad incumbent
Description

Blueprint Medicines is a larger precision oncology company with approved targeted small-molecule therapies. While targeting different mechanisms, it serves as a comparable business model benchmark for clinical-stage-to-commercial targeted oncology biotechs in EPICS' competitive set.

TypeRegional player
Description

iTeos Therapeutics is a Belgian clinical-stage immuno-oncology biotech. While its mechanism differs, it shares EPICS' Belgian biotech ecosystem, similar company stage profile, and similar oncology-focused small-molecule pipeline approach.

TypeRegional player
Description

Crescendo Biologics is a UK-based clinical-stage biotech with T-cell engagers in oncology. Comparable as a European clinical-stage oncology biotech with similar headcount scale and capital profile, though addressing different mechanisms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epic Therapeutics

Clinical-Stage Oncology Biopharmaceuticalsepicstherapeutics.com

Epic Therapeutics (EPICS) is a Belgian clinical-stage biotechnology company developing small-molecule METTL3 inhibitors (lead EP102) and GPCR modulators (EP282, EP601) to treat advanced solid tumors and autoimmune/inflammatory diseases. Founded 2018, headquartered in Gosselies, Belgium; lead asset entered first-in-patient trials in 2025.

What Epic Therapeutics does

EPICS Therapeutics SA is a Belgian clinical-stage biotechnology company founded in April 2018 and headquartered in Gosselies, Belgium. The company develops a pipeline of small-molecule therapeutics targeting RNA epigenetic regulation — specifically the m6A epitranscriptome via METTL3 inhibition — and complementary G-protein-coupled receptor (GPCR) pathways for the treatment of cancer and autoimmune/inflammatory disease. Its lead clinical candidate, EP102, is an oral, selective, best-in-class METTL3 inhibitor that entered first-in-patient trials in September 2025 across 12 hospital sites in 5 European countries (Belgium, Netherlands, Spain, Czech Republic, France), targeting advanced solid tumors including NSCLC, pancreatic, ovarian, and colorectal cancer. The pipeline also includes EP282, a first-in-class oral FFAR2 agonist for autoimmune disease (Phase I completed, positioned as Phase II-ready), and EP601, an oral GPR84 agonist in preclinical development for immuno-oncology and neuroinflammation. EPICS also operates the wholly-owned EuroscreenFast Business Services Unit, which offers GPCR screening services to external pharma and biotech clients.

The company's underlying technology platforms combine an "epitranscriptome" target class (RNA-modifying enzymes that write, read, or erase m6A marks) with GPCR modulation, intentionally positioning the company beyond DNA- and protein-targeted approaches. Pipeline assets were largely seeded by the December 2018 acquisition of Ogeda SA's assets, and the operational team — including the inventor of fezolinetant — carries significant prior drug-development experience.

The business model is pre-revenue and discovery-and-development oriented, with future revenue expected to come from product sales following regulatory approval and potential licensing or partnership transactions. There is no direct pricing or commercial sales operation; distribution today occurs via regulated clinical trial channels in Europe, with an additional service-revenue stream from EuroscreenFast's GPCR screening unit. Go-to-market is enterprise-style, with direct engagement of oncology Key Opinion Leaders, academic medical centers, and regulators, supplemented by scientific conferences (AACR, ASH, EORTC), peer-reviewed publications, and BIO investment conventions for investor and partner visibility.

Epic Therapeutics firmographics

Firmographics
Name
Epic Therapeutics
Legal name
Epics Therapeutics SA
Website
https://epicstherapeutics.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Epic Therapeutics (EPICS) is a Belgian clinical-stage biotechnology company developing small-molecule METTL3 inhibitors (lead EP102) and GPCR modulators (EP282, EP601) to treat advanced solid tumors and autoimmune/inflammatory diseases. Founded 2018, headquartered in Gosselies, Belgium; lead asset entered first-in-patient trials in 2025.
Ownership category
akta.pro rank

Epic Therapeutics industry classification

Industry
Product category
Clinical-Stage Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Small molecule therapeutics
  • RNA epigenetics drugs
  • METTL3 inhibitor oncology
  • Clinical stage biotechnology
  • Epitranscriptome drug discovery

Where Epic Therapeutics is headquartered

Location

Headquarters

HQ city
Gosselies
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Epic Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Drug Development: EPICS Therapeutics is a pre-revenue clinical-stage biotechnology company developing small molecule therapeutics. Revenue will be generated through product sales following regulatory approval, as well as potential licensing deals and partnerships for its pipeline programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Epic Therapeutics product offering

Product offering

Core offering

Epic Therapeutics is a clinical-stage biotechnology company developing small-molecule drugs targeting RNA epigenetics (epitranscriptome) and GPCR pathways for cancer and autoimmune disease. Its lead asset EP102 is a best-in-class, orally available METTL3 inhibitor now in first-in-patient clinical evaluation in solid tumors (NSCLC, pancreatic, ovarian, colorectal), supported by Phase II-ready EP282 (FFAR2 agonist) and preclinical EP601 (GPR84 agonist).

Product overview

EPICS Therapeutics is a clinical-stage biotechnology company developing a pipeline of small-molecule drugs targeting RNA epigenetics and G-protein-coupled receptor (GPCR) mechanisms for cancer and autoimmune disease treatment. The core portfolio includes EP102 (METTL3 inhibitor, first-in-patient clinical trial for solid tumors), EP282 (FFAR2 agonist, Phase II ready for autoimmune diseases), and EP601 (GPR84 agonist, preclinical for oncology and autoimmune diseases). The RNA epigenetics platform targets the epitranscriptome to modulate RNA processing and gene expression, while the GPCR program extends this epigenetic vision to complementary signaling pathways.

Differentiator

Problem solved

Functional benefit

Products and services

  • EP102 (METTL3 Inhibitor) Best-in-class, potent, selective, and orally available small-molecule inhibitor of the METTL3 enzyme that installs the m6A mark on messenger RNA, reprogramming tumor biology at the RNA level. EP102 is the company's lead clinical candidate for advanced solid tumors including NSCLC, pancreatic, ovarian, and colorectal cancers.
  • EP282 (FFAR2 Agonist) First-in-class small-molecule FFAR2 (Free Fatty Acid Receptor 2) agonist targeting the microbiome-immune axis for treatment of autoimmune and inflammatory diseases, including ulcerative colitis and C. difficile infection; also has potential in colorectal cancer. Ready for Phase II clinical development.
  • EP601 (GPR84 Agonist) Potent, selective, and orally available GPR84 agonist designed to activate or restrain immune responses, positioned at the intersection of metabolism, inflammation, and innate immunity, with therapeutic potential in oncology (tumor microenvironment reprogramming) and autoimmune diseases. In active preclinical development.
  • EuroscreenFast GPCR Screening Services GPCR screening and assay development services offered to worldwide pharma and biotech clients through Epic's wholly-owned EuroscreenFast Business Services Unit.

Quantifiable outcome

  • EP102 demonstrated near-complete tumor growth suppression in xenograft studies
  • +3 more outcomes

Companies that use Epic Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Epic Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Epic Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, major and supporting.

  • Cresset DiscoverycoreTechnology or Integration · 8 December 2025Computational drug design partnership where Cresset's integrated modeling workflow combining molecular modeling and proprietary technology (Electrostatic Complementarity) accelerated the discovery and optimization of EPICS' METTL3 inhibitor compounds. The iterative process of in silico design and biological testing supported efficient hit identification and lead optimization.
  • Ogeda SA (Astellas acquisition)majorStrategic or Co-development PartnerEPICS acquired Ogeda SA's former assets in December 2018, including research stage programs and the EuroscreenFast Business Services Unit. Ogeda's former CEO Jean Combalbert became CEO of EPICS. Several key EPICS team members (including Graeme Fraser, Guillaume Dutheuil, Vincent Lannoy, Catherine Sorlet) previously worked at Ogeda, which was acquired by Astellas for 800M EUR in 2017.
  • François Fuks (ULB Cancer Research Center)coreStrategic or Co-development PartnerClinical Scientific Advisor to EPICS - Professor at Free University of Brussels and Director of ULB Cancer Research Center. His work is devoted to epigenetics and its role in cancer. Performed doctoral research at German Cancer Research Center under Harald zur Hausen (2008 Nobel Prize in Medicine). Serves as scientific founder/advisor providing expertise in epigenetics.
  • Memorial Sloan Kettering Cancer Center (MSK) - David Scheinberg & Omar Abdel-WahabcoreStrategic or Co-development PartnerClinical Advisory Board members from MSK: David A. Scheinberg (Vincent Astor Chair, Deputy Director for Therapeutic Discovery at Sloan Kettering Institute) and Omar Abdel-Wahab (Evin Family Chair of Molecular Pharmacology, Chair of Molecular Pharmacology Program). Both are physician-scientists specializing in novel therapeutic approaches for leukemia and cancer with extensive research programs.
  • VHIO (Vall d'Hebron Institute of Oncology) - Elena GarraldacoreStrategic or Co-development PartnerClinical Advisory Board member Elena Garralda serves as Director of Molecular Cancer Therapy Research Unit (UITM) - CaixaResearch, Co-Director of Clinical Research Program, and Head of Early Drug Development at VHIO. She coordinates phase I program with expertise in immuno-oncology and first-in-human studies.
  • Curve Therapeutics - Rab PrinjhasupportingStrategic or Co-development PartnerClinical Advisory Board member Rab Prinjha is currently Chief Research and Development Officer at Curve Therapeutics, former head of GSK's Immunology Research Unit and elected fellow of the Academy of Medical Sciences. Has extensive record of successful leadership with multiple first-in-class epigenetic target inhibitors progressed from discovery to beyond Phase 2.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Epic Therapeutics competitors and assessment

Company assessment

Direct peers

  • STORM Therapeutics: STORM Therapeutics is the closest direct competitor to EPICS in RNA epitranscriptomics, developing small-molecule METTL3 inhibitors (STC-15) that are also in Phase I clinical trials for solid tumors and leukemia. Both companies target the same epitranscriptome mechanism with oral small molecules.
  • Accent Therapeutics: Accent Therapeutics develops precision oncology drugs targeting RNA-modifying proteins including METTL3 and other epitranscriptome regulators. As a US-based, well-capitalized competitor in the same therapeutic axis, it is directly comparable to EPICS' EP102 program.
  • Domain Therapeutics: Domain Therapeutics is a French biotech specializing in GPCR drug discovery and development, directly comparable to EPICS' GPCR programs (EP282 FFAR2, EP601 GPR84) and its inherited EuroscreenFast GPCR screening capabilities. Both operate in European biotech ecosystems with similar GPCR target portfolios.
  • Twentyeight-Seven Therapeutics: Twentyeight-Seven Therapeutics focused on RNA modifying proteins (initially METTL3) for oncology before being acquired by Roche. Directly comparable to EPICS as a small-molecule developer targeting RNA epigenetic regulators in cancer.

Emerging players

  • Tango Therapeutics: Tango Therapeutics is a clinical-stage oncology biotech focused on synthetic lethal targets, with a similar small-molecule targeted oncology strategy and similar stage profile as EPICS. While mechanism differs, the business model and target patient populations overlap substantially.
  • Repare Therapeutics: Repare Therapeutics develops precision oncology drugs targeting DNA damage response pathways — directly overlapping with EPICS' positioning of EP102 in tumors where METTL3 dysregulation intersects with DDR pathways. Both companies are clinical-stage with similar oncology indications in scope.

Broad incumbents

  • Sosei Heptares: Sosei Heptares is a leading GPCR-targeted therapeutics company with a broader portfolio than EPICS' GPCR programs (EP282, EP601). It provides a benchmark for the commercial potential of GPCR-focused drug discovery and is comparable on the GPCR technology axis.
  • Blueprint Medicines: Blueprint Medicines is a larger precision oncology company with approved targeted small-molecule therapies. While targeting different mechanisms, it serves as a comparable business model benchmark for clinical-stage-to-commercial targeted oncology biotechs in EPICS' competitive set.

Regional players

  • iTeos Therapeutics: iTeos Therapeutics is a Belgian clinical-stage immuno-oncology biotech. While its mechanism differs, it shares EPICS' Belgian biotech ecosystem, similar company stage profile, and similar oncology-focused small-molecule pipeline approach.
  • Crescendo Biologics: Crescendo Biologics is a UK-based clinical-stage biotech with T-cell engagers in oncology. Comparable as a European clinical-stage oncology biotech with similar headcount scale and capital profile, though addressing different mechanisms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Epic Therapeutics social profiles

Digital presence

Epic Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epic Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Epic Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Epic Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epic Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epic Therapeutics

What does Epic Therapeutics do?

Epic Therapeutics is a clinical-stage biotechnology company developing small-molecule drugs targeting RNA epigenetics (epitranscriptome) and GPCR pathways for cancer and autoimmune disease. Its lead asset EP102 is a best-in-class, orally available METTL3 inhibitor now in first-in-patient clinical evaluation in solid tumors (NSCLC, pancreatic, ovarian, colorectal), supported by Phase II-ready EP282 (FFAR2 agonist) and preclinical EP601 (GPR84 agonist).

Is Epic Therapeutics a public or private company?

Epic Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Epic Therapeutics founded?

Epic Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is Epic Therapeutics based?

Epic Therapeutics is headquartered in Gosselies, Belgium, in the Europe region.

How does Epic Therapeutics make money?

One revenue line is on record: pharmaceutical Drug Development.

Who are Epic Therapeutics's main competitors?

Direct peers on record are STORM Therapeutics, Accent Therapeutics, Domain Therapeutics and Twentyeight-Seven Therapeutics. Emerging players are Tango Therapeutics and Repare Therapeutics. Broad incumbents are Sosei Heptares and Blueprint Medicines. Regional players are iTeos Therapeutics and Crescendo Biologics.

Does Epic Therapeutics have an API?

No public API is recorded for Epic Therapeutics.

What industry is Epic Therapeutics in?

Epic Therapeutics's product category is Clinical-Stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals